Table 3.
Molecularly targeted agents in antiangiogenic therapy
| Agent | Target(s) |
|---|---|
| Bevacizumab | VEGF-A |
| Aflibercept (VEGF-Trap) | VEGF |
| Vandetanib | VEGFR, EGFR |
| Pazopanib | VEGFR, PDGFR, c-kit |
| Cediranib | VEGFR, PDGFR, c-kit |
| Vatalanib | VEGFR, PDGFR, c-kit |
| CT322 | VEGFR |
| Brivanib | VEGFR |
| DC101 | VEGFR |
| XL184 | c-met, VEGFR |
| XL880 | c-met, VEGFR, PDGFR, Tie-2 |
| Gefitinib | HER1/EGFR, Ras |
| Erlotinib | HER1/EGFR, Ras |
| Imatinib | PDGFRa, c-kit, BCR-ABL |
| MLN518 | PDGFR, Fit-3, c-kit |
| AEE788 | EGFR, VEGFR |
| Cetuximab | EGFR |
| Sorafenib | VEGFR, PDGFR, c-kit, Raf |
| Sunitinib | VEGFR, PDGFR, c-kit, FLT-3 |
| AMG-102 | HGF/SF |
| Cilengitide | αvβ3 and αvβ5 |
| ATN-161 | α5β1 |
Abbreviations: EGFR, epidermal growth factor receptor; HER, human epidermal receptor; HGF, hepatocyte growth factor; PDGFR, platelet-derived growth factor receptor; SF, scatter factor; VEGF, vascular endothelial growth factor.